MYRIAD

    

Myriad is a biopharmaceutical company focused on the development of novel healthcare products. In addition to an expanding preclinical pipeline, our drug discovery and development is strong in the areas of Alzheimer's disease, cancer and antivirals. We also develop and market predictive and personalized medicine products such as:

BRACAnalysis MELARIS COLARIS AP COLARIS
A genetic test for hereditary breast and ovarian cancer A genetic test for hereditary melanoma A genetic test for adenomatous polyposis syndromes A genetic test for hereditary nonpolyposis colorectal cancer (HNPCC)
TheraGuide 5-FU
A genetic test to
predict toxicity to 5-FU/capecitabine-based chemotherapy


Myriad Genetics at Bank of America 2008 Health Care Conference
Myriad Genetics 3rd Quarter Fiscal 2008 Financial Results Conference Call

Be Ready Against Cancer

6-May-2008 Myriad Genetics Reports Results for Third Quarter of Fiscal 2008
23-Apr-2008 Myriad Genetics Announces Third Quarter Fiscal 2008 Financial Results Conference Call
6-Mar-2008 Myriad Genetics to Present at the Lehman Brothers Healthcare Conference on March 19, 2008
© 2008 Myriad Genetics, Inc.